Aclaris Therapeutics (NASDAQ: ACRS)
Aclaris Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aclaris Therapeutics Company Info
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
News & Analysis
Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday
A bull on the company became more positive on its prospects.
Why Aclaris Therapeutics Topped the Market on Tuesday
Investors were cheered by the latest laboratory news from the company.
Why Aclaris Therapeutics Is Crashing Today
The company announced disappointing results from a phase 2a clinical study.
Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today
Investors are excited about the biotech's clinical trial results.
Here's Why Aclaris Therapeutics Stock Collapsed Today
A mid-stage trial failure has investors questioning the company's approach.
Could These 2 Biotech Stocks Really Double Your Money?
Analyst price targets for these two biotechs suggest they could double your money. Here's what you need to know.
Why Aclaris Therapeutics, Inc. Stock Is Down Today
The pharma's shares dipped on a $65 million capital raise.
The Best IPOs of 2015
2015 was not a particularly strong year for IPOs, but these five did quite well.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.